Beal F[au] - Search Results

Year	Number of Results
1896	1
1953	3
1954	1
1955	3
1956	2
1964	2
1965	3
1966	1
1968	3
1969	1
1970	2
1971	1
1973	3
1976	2
1997	1
1998	1
2001	1
2005	2
2006	2
2008	1
2011	1
2012	1
2014	2
2016	1
2017	2
2019	1
2020	3
2021	1
2022	3
2023	1

1

A Useful Blood Flow Restriction Training Risk Stratification for Exercise and Rehabilitation.

Nascimento DDC, Rolnick N, Neto IVS, Severin R, Beal FLR. Nascimento DDC, et al. Among authors: beal flr. Front Physiol. 2022 Mar 11;13:808622. doi: 10.3389/fphys.2022.808622. eCollection 2022. Front Physiol. 2022. PMID: 35360229 Free PMC article. Review.

2

Work styles.

Beal FC. Beal FC. Am J Health Syst Pharm. 1997 Dec 1;54(23):2680, 2683. doi: 10.1093/ajhp/54.23.2680. Am J Health Syst Pharm. 1997. PMID: 9408511 No abstract available.

3

Fifteen-minute consultation: An approach to the child with nephrocalcinosis.

Beal F, Patel A, Hulton SA. Beal F, et al. Arch Dis Child Educ Pract Ed. 2022 Aug 2:edpract-2022-324066. doi: 10.1136/archdischild-2022-324066. Online ahead of print. Arch Dis Child Educ Pract Ed. 2022. PMID: 35918124

4

Perspectives on the Therapeutic Benefits of Arginine Supplementation in Cancer Treatment.

Beal FLR, Beal PR, Beal JR, Carvalho-Neves N, Franco OL, Silva ON. Beal FLR, et al. Endocr Metab Immune Disord Drug Targets. 2019;19(7):913-920. doi: 10.2174/1871530319666190116121451. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30652655 Review.

5

Portal to Alzheimer's disease.

Starkov AA, Beal FM. Starkov AA, et al. Among authors: beal fm. Nat Med. 2008 Oct;14(10):1020-1. doi: 10.1038/nm1008-1020. Nat Med. 2008. PMID: 18841137 Free PMC article.

6

Field-based versus laboratory-based estimates of muscle quality index in adolescents with and without Down syndrome.

Melo GLR, Moraes MR, Nascimento EF, Boato EM, Beal FLR, Stone W, da Cunha Nascimento D. Melo GLR, et al. Among authors: beal flr. J Intellect Disabil Res. 2022 Dec;66(12):1000-1008. doi: 10.1111/jir.12959. Epub 2022 Jun 23. J Intellect Disabil Res. 2022. PMID: 35734961

7

Neuroprotective agents for clinical trials in ALS: a systematic assessment.

Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, Cudkowicz ME. Traynor BJ, et al. Among authors: beal f. Neurology. 2006 Jul 11;67(1):20-7. doi: 10.1212/01.wnl.0000223353.34006.54. Neurology. 2006. PMID: 16832072 Review.

8

The proteasomal inhibition model of Parkinson's disease: "Boon or bust"?

Beal F, Lang A. Beal F, et al. Ann Neurol. 2006 Aug;60(2):158-61. doi: 10.1002/ana.20939. Ann Neurol. 2006. PMID: 16862578 No abstract available.

9

[Orbitoretinal angiomatosis].

Constantinidès G, Béal F, Capier. Constantinidès G, et al. Among authors: beal f. Bull Soc Ophtalmol Fr. 1971 Jul-Aug;71(7):741-2. Bull Soc Ophtalmol Fr. 1971. PMID: 5144788 French. No abstract available.

10

Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease.

Fil D, DeLoach A, Yadav S, Alkam D, MacNicol M, Singh A, Compadre CM, Goellner JJ, O'Brien CA, Fahmi T, Basnakian AG, Calingasan NY, Klessner JL, Beal FM, Peters OM, Metterville J, Brown RH Jr, Ling KKY, Rigo F, Ozdinler PH, Kiaei M. Fil D, et al. Among authors: beal fm. Hum Mol Genet. 2017 Feb 15;26(4):686-701. doi: 10.1093/hmg/ddw429. Hum Mol Genet. 2017. PMID: 28040732 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results